• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

APOB Gene Record

  • Summary
  • Interactions
  • Claims
  • APOB 338 Druggable Genome

    Alternate Names:

    338
    APOLIPOPROTEIN B
    APOB
    FLDB
    LDLCQ4
    apoB-100
    apoB-48
    107730
    603
    ENSG00000084674
    OTTHUMG00000090785
    APOLIPOPROTEIN B-100 PRECURSOR (APO B-100) [CONTAINS: APOLIPOPROTEIN B-48 (APO B-48)]. [SOURCE:UNIPROT/SWISSPROT;ACC:P04114]
    APOLIPOPROTEIN B-100
    P04114
    APOB_HUMAN
    PA50
    APOLIPOPROTEIN B-48
    T07533
    FCHL2

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Target Class Miscellaneous
    Target Subclass Enzyme cofactor
    Interpro Acc IPR001747
    Interpro Short Name Lipid_transpt_N
    Interpro Name Lipid transport protein, N-terminal
    Uniprot Status Swiss-Prot
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level
    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Lau et al., 1995, Ethanol modulates apolipoprotein B mRNA editing in the rat., J. Lipid Res.
    Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.
    Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.
    Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.
    Lam et al., 2005, Fourier transform infrared spectroscopy evaluation of low density lipoprotein oxidation in the presence of quercetin, catechin, and alpha-tocopherol., Lipids
    Parhofer et al., 1993, Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia., Clin Investig
    Wang et al., 1995, Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes., Arterioscler. Thromb. Vasc. Biol.
    Mabile et al., 1995, alpha-Tocopherol and trolox block the early intracellular events (TBARS and calcium rises) elicited by oxidized low density lipoproteins in cultured endothelial cells., Free Radic. Biol. Med.
    Sjöberg et al., 1992, Effects of growth hormone on apolipoprotein-B (apoB) messenger ribonucleic acid editing, and apoB 48 and apoB 100 synthesis and secretion in the rat liver., Endocrinology
    Yee et al., 2002, Green tea catechins decrease apolipoprotein B-100 secretion from HepG2 cells., Mol. Cell. Biochem.
    Huff et al., 1985, Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs., J. Lipid Res.
    Petit et al., 2003, Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study., J. Lipid Res.
    Watts et al., 2003, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome., Diabetes
    Field et al., 1995, Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of p-glycoprotein., J. Lipid Res.
    Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens
    Bakillah et al., 1998, Lysine and arginine residues in the N-terminal 18% of apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein., Biochemistry
    Krul et al., 1988, Regional specificities of monoclonal anti-human apolipoprotein B antibodies., J. Lipid Res.
    Mohammadi et al., 1998, Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells., Arterioscler. Thromb. Vasc. Biol.
    Miltiadous et al., 2005, Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia., Pharmacogenet. Genomics
    Tsimikas et al., 2004, High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial., Circulation
    Telford et al., 2003, Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB., J. Lipid Res.
    Chan et al., 2002, Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia., Diabetes
    Forster et al., 2002, Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates., Atherosclerosis
    Pal et al., 2002, Cholesterol esters regulate apoB48 secretion in CaCo2 cells., Atherosclerosis
    Burnett et al., 1999, The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs., Endocrinology
    Wilcox et al., 1999, Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin., J. Lipid Res.
  • CHOLESTYRAMINE   APOB

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3906004


    Sources:
    NCI

  • MIPOMERSEN   APOB

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ISIS 301012
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • LOMITAPIDE   APOB

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRBESARTAN   APOB

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15614026


    Sources:
    PharmGKB

  • VITAMIN E   APOB

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7649489


    Sources:
    NCI

  • ATORVASTATIN   APOB

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9598838 15864114 15353498 12562847 12145148 12119202 11882317 10537160 10357840


    Sources:
    NCI

  • HEPARIN   APOB

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9521691 2457642


    Sources:
    NCI

  • FENOFIBRATE   APOB

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12606523


    Sources:
    NCI PharmGKB

  • LOVASTATIN   APOB

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662319 2351867 1588827


    Sources:
    NCI

  • NEVIRAPINE   APOB

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12869587


    Sources:
    NCI

  • TRIFLUOPERAZINE   APOB

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7595077


    Sources:
    NCI

  • EPIGALOCATECHIN GALLATE   APOB

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11936850


    Sources:
    NCI

  • PRAVASTATIN   APOB

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8312689


    Sources:
    NCI

  • HYDROCORTISONE   APOB

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1597147


    Sources:
    NCI

  • WARFARIN   APOB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • QUERCETIN   APOB

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16149735


    Sources:
    NCI

  • DEXAMETHASONE   APOB

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7670964


    Sources:
    NCI

  • ALCOHOL   APOB

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8576634


    Sources:
    NCI

  • Ensembl: ENSG00000084674

    • Version: 101_38

    Alternate Names:
    APOB Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P04114

    • Version: January-2014

    Alternate Names:
    APOB Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Enzyme cofactor

    Publications:

  • RussLampel: ENSG00000084674

    • Version: 26-July-2011

    Alternate Names:
    APOLIPOPROTEIN B-100 PRECURSOR (APO B-100) [CONTAINS: APOLIPOPROTEIN B-48 (APO B-48)]. [SOURCE:UNIPROT/SWISSPROT;ACC:P04114] Description
    ENSG00000084674 Ensembl Gene Id
    APOB Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P04114

    • Version: 11-September-2012

    Alternate Names:
    P04114 Uniprot Accession
    ENSG00000084674 Ensembl Gene Id
    APOB_HUMAN Uniprot Id

    Gene Info:
    Interpro Acc IPR001747
    Interpro Short Name Lipid_transpt_N
    Interpro Name Lipid transport protein, N-terminal

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: APOB

    • Version: 18-August-2020

    Alternate Names:
    PA50 PharmGKB ID

    Gene Info:

    Publications:
    Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens

  • NCI: APOB

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.
    Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.
    Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.

  • HingoraniCasas: ENSG00000084674

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000084674 Gene Symbol
    APOB Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: APOB

    • Version: 11-November-2018

    Alternate Names:
    APOB Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Apolipoprotein B-100

    • Version: 2020.06.01

    Alternate Names:
    APOB TTD Gene Abbreviation
    T07533 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21